13 Results for "

wildtype HER2

" in MedChemExpress (MCE) Product Catalog:
Products (13)

13 Results for "wildtype HER2" in MCE Product Catalog:

  • Targets Recommended:
12
12 Publications Verification
Cat. No.: HY-135815
CAS No.: 1847461-43-1
Purity:  99.60%
Synonyms: TAK-788; AP32788
Target:  

EGFR

Research Areas:  

Cancer

Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib can be used in NSCLC research .
loading...
    loading...
12
12 Publications Verification
Cat. No.: HY-135815A
CAS No.: 2389149-74-8
Purity:  99.83%
Synonyms: TAK-788 succinate; AP32788 succinate
Target:  

EGFR

Research Areas:  

Cancer

Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research .
loading...
    loading...
Cat. No.: HY-164718
CAS No.: 2521285-05-0
Synonyms: BAY 2927088
Target:  

EGFR

Research Areas:  

Cancer

Sevabertinib (BAY 2927088) is an orally active and reversible dual EGFR-HER2 inhibitor (IC 50 <0.5 nM for wild-type HER2, HER2 A775insYVMA, wild-type EGFR, and EGFR D770_N771insSVD). Sevabertinib has anticancer activity against lung cancer .
loading...
    loading...
Cat. No.: HY-131864
CAS No.: 2230821-38-0
Purity:  99.71%
Target:  

PROTACs EGFR

Research Areas:  

Cancer

SJF-1528 (PROTAC 1) is a potent EGFR PROTAC degrader with DC50 values of 39.2 nM and 736.2 nM for wild-type EGFR in OVCAR8 cells and Exon 20 Ins mutant EGFR in HeLa cells. SJF-1528 also degrades HER2. SJF-1528 promotes ubiquitination and degradation of EGFR and can be used in breast cancer research .
loading...
    loading...
Cat. No.: HY-153856
CAS No.: 2451398-65-3
Target:  

EGFR

Research Areas:  

Cancer

TAS2940 is a brain-penetrable, orally active, irreversible and selective pan-ERBB inhibitor. TAS2940 against wild-type HER2, HER2 V777L, and A775_G776insYVMA with IC50 values of 5.6 nM, 2.1 nM, and 1.0 nM, respectively. TAS2940 can be used for the study of tumors with HER2 and EGFR aberrations .
loading...
    loading...
Cat. No.: HY-131864A
Purity:  98.90%
Target:  

PROTACs EGFR

Research Areas:  

Cancer

SJF-1528 (PROTAC 1) hemihydrate is a potent EGFR PROTAC degrader with DC50 values of 39.2 nM and 736.2 nM for wild-type EGFR in OVCAR8 cells and Exon 20 Ins mutant EGFR in HeLa cells. SJF-1528 hemihydrate also degrades HER2. SJF-1528 hemihydrate promotes ubiquitination and degradation of EGFR and can be used in breast cancer research .
loading...
    loading...
Cat. No.: HY-164392
CAS No.: 1451370-01-6
Target:  

EGFR Apoptosis

Research Areas:  

Cancer

TAS-121 is an orally active, selective, covalent, third-generation mutant EGFR-tyrosine kinase inhibitor (EGFR-TKI). TAS-121 inhibits the L858R mutation (IC50=1.7 nM), Ex19del mutation (IC50=2.7 nM), L858R/T790M mutation (IC50=0.56 nM) and Ex19del/T790M mutation (IC50=1.1 nM) and wild-type EGFR (IC50=8.2 nM). TAS-121 inhibits HER2 and HER4 with IC50s of 110 and 2.6 nM, respectively. TAS-121 inhibits phosphorylation of EGFR and its downstream signaling targets to block cell proliferation. TAS-121 induces apoptosis and displays antitumor activity in SW48 (EGFR G719S) and NCI-H1975 (EGFR L858R/T790M) xenograft models .
loading...
    loading...
Cat. No.: HY-153856A
CAS No.: 2758034-98-7
Target:  

EGFR

Research Areas:  

Cancer

TAS2940 fumarate is a brain-penetrable, orally active, irreversible and selective pan-ERBB inhibitor. TAS2940 fumarate against wild-type HER2, HER2 V777L, and A775_G776insYVMA with IC50 values of 5.6 nM, 2.1 nM, and 1.0 nM, respectively. TAS2940 fumarate can be used for the study of tumors with HER2 and EGFR aberrations .
loading...
    loading...
Cat. No.: HY-135815B
CAS No.: 2389149-85-1
Synonyms: TAK-788 mesylate; AP32788 mesylate
Target:  

EGFR

Research Areas:  

Cancer

Mobocertinib (TAK-788) mesylate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib mesylate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib mesylate can be used in NSCLC research .
loading...
    loading...
Cat. No.: HY-135815R
CAS No.: 1847461-43-1
Synonyms: TAK-788 (Standard); AP32788 (Standard)
Research Areas:  

Cancer

Mobocertinib (Standard) is the analytical standard of Mobocertinib. This product is intended for research and analytical applications. Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib can be used in NSCLC research .
loading...
    loading...
Cat. No.: HY-177895
CAS No.: 3031413-24-5
Target:  

EGFR

Research Areas:  

Cancer

IAM1363 is a selective, irreversible, and blood-brain barrier-permeable HER2 inhibitor . IAM1363 targets wild-type HER2 and oncogenic HER2 mutants (including exon 20 mutations), with no off-target EGFR inhibitory activity. IAM1363 can be used to study HER2-driven solid tumors, including colorectal cancer, non-small cell lung cancer, bladder cancer, and breast cancer .
loading...
    loading...
Cat. No.: HY-185276
CAS No.: 2989904-86-9
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-204 (Example 1) is a HER2 exon 20 mutation inhibitor with selectivity for wild-type EGFR. EGFR-IN-204 exerts antiproliferative effects on cells dependent on HER2 exon 20 YVMA insertion mutation and wild-type HER2, and shows strong selectivity over cells dependent on wild-type EGFR. EGFR-IN-204 is applicable to non-small cell lung cancer research .
loading...
    loading...
Cat. No.: HY-135815AR
CAS No.: 2389149-74-8
Synonyms: TAK-788 succinate (Standard); AP32788 succinate (Standard)
Research Areas:  

Cancer

Mobocertinib (succinate) (Standard) is the analytical standard of Mobocertinib (succinate). This product is intended for research and analytical applications. Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research .
loading...
    loading...
  • 1